# A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

> **NCT05152576** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 124 (actual)

## Conditions studied

- Forehead Lines

## Interventions

- **DRUG:** OnabotulinumtoxinA X
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05152576
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2022-09-06
- **Final completion:** 2022-09-06
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152576, "A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05152576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*